GLP-1s in the pipeline

A strong product pipeline is anticipated to propel the growth of the GLP-1 agonist market.

Additional innovative products in terms of formulations, improved bioavailability, combination therapies, and route of administration are being developed. Staying vigilant in monitoring this robust pipeline is critical to helping proactively manage this complex class of drugs by helping to ensure clinical impact while minimizing cost.

	Drug	Dosage	Manufacturer	Type 2 Diabetes	Obesity
PHASE 3	**CagriSema** (cagrilintide/semaglutide)*		Novo Nordisk	X	X
	IcoSema (insulin icodec/semaglutide)*		Novo Nordisk	X	
	orforglipron		Eli Lilly	X	X
	retatrutide		Eli Lilly		X
	semaglutide		Novo Nordisk	FDA approved 9/20/2019 (Rybelsus)	X†
	tirzepatide		Eli Lilly	FDA approved 5/13/2022 (Mounjaro)	X†
PHASE 2	**AMG133**		Amgen		X
	danuglipron		Pfizer	X	X
	pemvidutide		Altimmune		X
	retatrutide		Eli Lilly	X	
	survodutide		Boehringer Ingelheim/ Zealand Pharma	X	X

In addition, GLP-1 manufacturers are seeking approval for supplemental indications including treatment of non-alcoholic steatohepatitis (NASH), obstructive sleep apnea, risk reduction for major adverse cardiovascular events, and peripheral arterial disease.

Many of these are likely to be approved or launched within the next two years.

CVS Pipeline Services anticipates that the financial impact of most is replacement spend within the pharmacy benefit, with the exception of Ozempic for NASH, which has received Breakthrough Therapy designation and would likely result in incremental spend.

* New combination of existing GLP-1 agonist.

† New formulation of existing GLP-1 agonist.

CVS caremark™